Pain Reduction and Changes in Upper Limb Function Produced by Over the Counter Oral Ibuprofen and Median Nerve Neural Mobilization Versus the Lack of Treatment, in Carpal Tunnel Syndrome.
Overview
- Phase
- Phase 4
- Intervention
- ibuprofen tablets
- Conditions
- Carpal Tunnel Syndrome
- Sponsor
- Universidad Europea de Madrid
- Enrollment
- 123
- Locations
- 1
- Primary Endpoint
- Distal upper limb pain
- Status
- Completed
- Last Updated
- 4 months ago
Overview
Brief Summary
In the present investigation, the pain reduction effect of median nerve neural mobilization and oral ibuprofen treatments will be compared to those produced by the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.
Detailed Description
The present randomized clinical trial will perform a comparison of the pain reduction effects produced by median nerve neural mobilization and oral ibuprofen treatments to the total lack of treatment in subjects diagnosed with carpal tunnel syndrome. Effects over the functionality of the affected upper limb will be evaluated and compared. Subjects will be invited to participate and randomly allocated to 3 different groups.
Investigators
Francisco Unda Solano
Biomedicine Doctorate Program Investigator
Universidad Europea de Madrid
Eligibility Criteria
Inclusion Criteria
- •Participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings).
- •Full understanding of written and spoken Spanish (language).
- •Participants must freely consent to participate.
- •The presence of positive Phalen and Tinel signs.
- •The presence of carpal tunnel syndrome signs and symptoms.
Exclusion Criteria
- •The lack to meet inclusion criterions.
- •The presence of cognitive impairment.
- •Upper limb surgery or trauma.
- •Pregnancy.
- •Deformities of the (affected) upper limb.
- •Recent skin injuries or infections (in the affected upper limb).
- •Autoimmune inflammatory conditions or flu type symptoms.
- •Allergy (or contraindication) to non steroidal anti inflammatory drugs (NSAID)
- •Participants must not be (during the present investigation) under any type of pain reducing treatment (conservative, homeopathic, invasive or not invasive).
- •Metabolic neuropathy.
Arms & Interventions
Ibuprofen
Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
Intervention: ibuprofen tablets
Median nerve neural mobilization
Median nerve neural mobilization non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
Intervention: Median nerve neural mobilization
Outcomes
Primary Outcomes
Distal upper limb pain
Time Frame: Changes from baseline (measured immediately before the application of the first treatment) and 60 minutes after the application of the last treatment.
Assessed through the visual analog scale (VAS). The VAS is a psychometric response scale. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured.The VAS is the most frequently used method to assess pain intensity. The scale will be displayed as a horizontal 100-mm line labelled at each end by descriptors such as 'no pain' (the minimum and best outcome possible) and 'worse pain ever' (maximum and worst outcome possible). The participant will mark the line to indicate pain severity and it is simply quantified by measuring the distance in millimeters from 0 (no pain) to the patient's marked rating.
Secondary Outcomes
- Upper limb function(Changes from baseline (measured immediately before the application of the first treatment), and at 60 minutes after the application of the last treatment)
- Work Status at baseline(Measured immediately before the application of the first treatment)
- Work Status post treatment(Measured immediatly after the application of the last treatment.)
- Change in Work Task (Job Type)(Measured immediatly after the application of the last treatment.)
- Tampa Scale for Kinesiophobia-17 (TSK-17)(Changes from baseline (measured immediately before the application of the first treatment), and at 60 minutes after the application of the last treatment.)